03:28:56 EDT Sun 01 Aug 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Wildflower Marijuana Inc
Symbol SUN
Shares Issued 30,006,770
Close 2015-12-08 C$ 0.135
Recent Sedar Documents

Wildflower enters research deal with Biologic

2015-12-09 07:37 ET - News Release

Mr. William MacLean reports

WILDFLOWER TO CONDUCT MEDICAL RESEARCH

Wildflower Marijuana Inc. has entered an agreement with Biologic Nutrigenomics Research Corp. to conduct medical research on Wildflower's products and to assist in new product development. Wildflower has been developing cannabis products to address demands in the nutraceutical, pharmacological and recreational cannabis sectors. The company intends to bring products to market that are backed by solid scientific study demonstrating their efficacy. By using a science-based approach, the company will be able to further enhance the effectiveness of all its products.

Franco Cavaleri, president and chief science officer at BNRC, stated: "As much as the current movement to legalize and make cannabis more readily available is an exciting business prospect, it is more important to take a serious leadership role in the mining of this natural medicine's full therapeutic potential to advance medical research and treatment of disease. Cannabis comprises a plethora of constituents that range in pharmacological activity from anti-inflammatory, analgesic (pain killing) and anti-cancer to neuro-protective and neuro-corrective. However, clinical and wet lab research reliability and repeatability have fallen short due to lack of standardization and sophistication of historical research models. With a corporate mission dedicated to extract the full pharmacological potential of this medicinal agent and some insight that gives us a head start with the right biological mechanisms and models, research using formal medical models to investigate novel cannabinoid-signalling pathways in the framework of complex disease pathologies to improve efficacy, reliability and acceptability in mainstream medicine [will allow the company] to better serve humanity and global health care with reliable, low-risk medicines exclusive to the Wildflower brand."

As part of this collaboration, Franco Cavaleri will be added to the Wildflower advisory board as its scientific and product development adviser. As a prominent nutraceutical biochemist, Mr. Cavaleri has had much success in developing products for the nutraceutical industry, garnering him widespread recognition in the health industry. He has won Gold, Silver and Bronze Alive Formulation awards, an annual event put on by the Alive Publishing Group that promotes and recognizes outstanding product innovation while enhancing the credibility of natural health products. As an entrepreneur he was successful in various start-ups from conceptualization to acquisition and merger. As a writer he wrote the best-selling book, "Potential Within: A Guide to Nutritional Empowerment."

President and chief executive officer of Wildflower, William MacLean, stated: "This new alliance is the launching pad for the next stage in our business plan. Franco brings a unique combination of academia and private sector experience that will provide an invaluable asset as we make a scientific approach to our product development a cornerstone of the company."

The agreement with BNRC is for a period of one year with automatic annual renewals. The company will issue 400,000 common shares as consideration for the agreement and grant 300,000 stock options at a price of 20 cents for a period of five years. The agreement is subject to raising sufficient proceeds to finance the first year of testing, including lab space, clinical technicians and other costs. The agreement also provides that if the company does a deal with a pharmaceutical company or another interested party based on the work done by BNRC, the company shall pay to BNRC 7.5 per cent of any consideration received from such deal with that company and 100,000 common shares.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.